S&P 500   3,370.32 (-0.09%)
DOW   27,869.99 (-0.10%)
QQQ   271.21 (-0.47%)
AAPL   453.99 (-1.32%)
MSFT   207.59 (-0.53%)
FB   259.54 (-0.67%)
GOOGL   1,502.93 (-0.90%)
AMZN   3,122.57 (-1.22%)
NVDA   461.13 (+0.74%)
CGC   17.15 (-0.98%)
BABA   251.93 (-0.71%)
TSLA   1,637.00 (+0.99%)
GE   6.64 (+0.61%)
MU   45.49 (-1.41%)
AMD   82.00 (+0.20%)
T   30.02 (+0.37%)
F   7.06 (+0.43%)
GILD   68.34 (+0.23%)
NFLX   481.11 (-0.05%)
DIS   130.89 (-0.05%)
BAC   26.38 (+0.11%)
BA   177.03 (+1.32%)
S&P 500   3,370.32 (-0.09%)
DOW   27,869.99 (-0.10%)
QQQ   271.21 (-0.47%)
AAPL   453.99 (-1.32%)
MSFT   207.59 (-0.53%)
FB   259.54 (-0.67%)
GOOGL   1,502.93 (-0.90%)
AMZN   3,122.57 (-1.22%)
NVDA   461.13 (+0.74%)
CGC   17.15 (-0.98%)
BABA   251.93 (-0.71%)
TSLA   1,637.00 (+0.99%)
GE   6.64 (+0.61%)
MU   45.49 (-1.41%)
AMD   82.00 (+0.20%)
T   30.02 (+0.37%)
F   7.06 (+0.43%)
GILD   68.34 (+0.23%)
NFLX   481.11 (-0.05%)
DIS   130.89 (-0.05%)
BAC   26.38 (+0.11%)
BA   177.03 (+1.32%)
S&P 500   3,370.32 (-0.09%)
DOW   27,869.99 (-0.10%)
QQQ   271.21 (-0.47%)
AAPL   453.99 (-1.32%)
MSFT   207.59 (-0.53%)
FB   259.54 (-0.67%)
GOOGL   1,502.93 (-0.90%)
AMZN   3,122.57 (-1.22%)
NVDA   461.13 (+0.74%)
CGC   17.15 (-0.98%)
BABA   251.93 (-0.71%)
TSLA   1,637.00 (+0.99%)
GE   6.64 (+0.61%)
MU   45.49 (-1.41%)
AMD   82.00 (+0.20%)
T   30.02 (+0.37%)
F   7.06 (+0.43%)
GILD   68.34 (+0.23%)
NFLX   481.11 (-0.05%)
DIS   130.89 (-0.05%)
BAC   26.38 (+0.11%)
BA   177.03 (+1.32%)
S&P 500   3,370.32 (-0.09%)
DOW   27,869.99 (-0.10%)
QQQ   271.21 (-0.47%)
AAPL   453.99 (-1.32%)
MSFT   207.59 (-0.53%)
FB   259.54 (-0.67%)
GOOGL   1,502.93 (-0.90%)
AMZN   3,122.57 (-1.22%)
NVDA   461.13 (+0.74%)
CGC   17.15 (-0.98%)
BABA   251.93 (-0.71%)
TSLA   1,637.00 (+0.99%)
GE   6.64 (+0.61%)
MU   45.49 (-1.41%)
AMD   82.00 (+0.20%)
T   30.02 (+0.37%)
F   7.06 (+0.43%)
GILD   68.34 (+0.23%)
NFLX   481.11 (-0.05%)
DIS   130.89 (-0.05%)
BAC   26.38 (+0.11%)
BA   177.03 (+1.32%)
Log in

NYSEAMERICAN:ATNMActinium Pharmaceuticals News Headlines

$9.77
-0.14 (-1.41 %)
(As of 08/14/2020 10:43 AM ET)
Add
Compare
Today's Range
$9.71
Now: $9.77
$10.15
50-Day Range N/A
52-Week Range
$4.71
Now: $9.77
$19.47
Volume3,875 shs
Average Volume397,533 shs
Market Capitalization$132.60 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Actinium Pharmaceuticals (NYSEAMERICAN ATNM) News Headlines

Source:
DateHeadline
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Hits New 12-Month High at $10.04Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Hits New 12-Month High at $10.04
americanbankingnews.com - August 11 at 11:59 AM
Actinium Pharmaceuticals to reverse split shares 1:30Actinium Pharmaceuticals to reverse split shares 1:30
seekingalpha.com - August 10 at 5:25 PM
Actinium Pharmaceuticals announces reverse stock split 1-for-30Actinium Pharmaceuticals announces reverse stock split 1-for-30
seekingalpha.com - August 10 at 5:25 PM
Actinium Pharmaceuticals, Inc. Announces Reverse Stock SplitActinium Pharmaceuticals, Inc. Announces Reverse Stock Split
finance.yahoo.com - August 10 at 5:25 PM
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Shares Gap Down to $0.43Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Shares Gap Down to $0.43
americanbankingnews.com - August 7 at 1:58 PM
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)  Shares Down 24.4% Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Shares Down 24.4%
americanbankingnews.com - August 6 at 8:58 PM
Actinium (ATNM) to Report Q2 Earnings: Whats in the Cards?Actinium (ATNM) to Report Q2 Earnings: What's in the Cards?
nasdaq.com - August 3 at 5:29 PM
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Shares Gap Up to $0.58Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Shares Gap Up to $0.58
americanbankingnews.com - August 3 at 4:33 PM
Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should KnowActinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know
finance.yahoo.com - July 28 at 9:04 PM
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Shares Gap Up to $0.53Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Shares Gap Up to $0.53
www.americanbankingnews.com - July 27 at 8:52 PM
Actinium Pharmaceuticals (ATNM) is a Great Momentum Stock: Should You Buy?Actinium Pharmaceuticals (ATNM) is a Great Momentum Stock: Should You Buy?
finance.yahoo.com - July 23 at 1:04 PM
Investors Purchase High Volume of Call Options on Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)Investors Purchase High Volume of Call Options on Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)
www.americanbankingnews.com - July 21 at 11:31 AM
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Shares Gap Up to $0.40Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Shares Gap Up to $0.40
www.americanbankingnews.com - July 20 at 2:37 PM
Actinium Pharmaceuticals, Inc. (ATNM) Shares March Higher, Can It Continue?Actinium Pharmaceuticals, Inc. (ATNM) Shares March Higher, Can It Continue?
finance.yahoo.com - July 20 at 2:32 PM
Is the Options Market Predicting a Spike in Actinium Pharmaceuticals (ATNM) Stock?Is the Options Market Predicting a Spike in Actinium Pharmaceuticals (ATNM) Stock?
finance.yahoo.com - June 16 at 12:37 AM
Actinium Pharmaceuticals (ATNM) Jumps: Stock Rises 6.7%Actinium Pharmaceuticals (ATNM) Jumps: Stock Rises 6.7%
finance.yahoo.com - June 9 at 10:20 AM
Benzingas Top Upgrades, Downgrades For June 4, 2020Benzinga's Top Upgrades, Downgrades For June 4, 2020
finance.yahoo.com - June 4 at 12:55 PM
Actinium Pharmaceuticals, Inc. Announces Closing of $31.6 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional SharesActinium Pharmaceuticals, Inc. Announces Closing of $31.6 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - April 24 at 5:38 PM
Actinium Pharma down 34% premarket after pricing equity offeringActinium Pharma down 34% premarket after pricing equity offering
seekingalpha.com - April 22 at 9:55 AM
Actinium Pharmaceuticals, Inc. Announces Pricing of $27.5 Million Public OfferingActinium Pharmaceuticals, Inc. Announces Pricing of $27.5 Million Public Offering
finance.yahoo.com - April 21 at 11:57 PM
Actinium Provides Update on Iomab-B SIERRA Trial and Expected Topline Results from Ad Hoc Analysis in 2020Actinium Provides Update on Iomab-B SIERRA Trial and Expected Topline Results from Ad Hoc Analysis in 2020
finance.yahoo.com - April 16 at 7:18 AM
Actinium Pharmaceuticals Announces First Patient Treated in Third and Final Dose Cohort of Actimab-A CLAG-M Combination Phase 1 Trial in Acute Myeloid LeukemiaActinium Pharmaceuticals Announces First Patient Treated in Third and Final Dose Cohort of Actimab-A CLAG-M Combination Phase 1 Trial in Acute Myeloid Leukemia
finance.yahoo.com - March 5 at 8:39 AM
Actinium (ATNM) to Report Q4 Earnings: What's in the Cards?Actinium (ATNM) to Report Q4 Earnings: What's in the Cards?
finance.yahoo.com - February 25 at 1:05 PM
ATNM Feb 2020 2.500 callATNM Feb 2020 2.500 call
finance.yahoo.com - February 22 at 10:41 PM
Actinium Presents Positive Findings from Mid-...Actinium Presents Positive Findings from Mid-...
www.benzinga.com - February 21 at 9:39 AM
Actinium Pharma up 17% premarket on encouraging Iomab-B dataActinium Pharma up 17% premarket on encouraging Iomab-B data
seekingalpha.com - February 21 at 9:39 AM
Actinium Presents Positive Findings from Mid-Point Analysis of Pivotal SIERRA Trial of Iomab-B at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT)Actinium Presents Positive Findings from Mid-Point Analysis of Pivotal SIERRA Trial of Iomab-B at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT)
finance.yahoo.com - February 21 at 9:39 AM
Actinium to Highlight Targeted Conditioning...Actinium to Highlight Targeted Conditioning...
www.benzinga.com - February 13 at 12:14 PM
Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting; Phase 3 SIERRA Trial Preliminary Results Selected for Oral PresentationActinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting; Phase 3 SIERRA Trial Preliminary Results Selected for Oral Presentation
finance.yahoo.com - February 13 at 12:14 PM
API Economy: Is It The Next Big Thing?API Economy: Is It The Next Big Thing?
www.forbes.com - January 18 at 5:15 PM
API Testing Market Analysis, Size, Share, Growth, Trends and Forecast to 2025API Testing Market Analysis, Size, Share, Growth, Trends and Forecast to 2025
www.marketwatch.com - January 18 at 12:15 PM
Actinium up 11% on gene therapy collaborationActinium up 11% on gene therapy collaboration
seekingalpha.com - January 13 at 4:35 PM
Actinium (ATNM) Upgraded to Strong Buy: Heres WhyActinium (ATNM) Upgraded to Strong Buy: Here's Why
www.nasdaq.com - January 13 at 4:35 PM
One Thing To Remember About The Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) Share PriceOne Thing To Remember About The Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) Share Price
finance.yahoo.com - January 13 at 4:35 PM
Actinium (ATNM) Upgraded to Strong Buy: Here's WhyActinium (ATNM) Upgraded to Strong Buy: Here's Why
finance.yahoo.com - January 13 at 4:35 PM
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
finance.yahoo.com - January 3 at 1:55 PM
Hedge Funds Have Never Been More Bullish On Actinium Pharmaceuticals Inc (ATNM)Hedge Funds Have Never Been More Bullish On Actinium Pharmaceuticals Inc (ATNM)
finance.yahoo.com - December 22 at 6:11 PM
Is Capstone Turbine Corporation (CPST) Going to Burn These Hedge Funds?Is Capstone Turbine Corporation (CPST) Going to Burn These Hedge Funds?
finance.yahoo.com - December 20 at 5:38 PM
Actinium Pharmaceuticals Announces Phase 3 SIERRA Trial Dosimetry Results Support Low Dose Iomab-B for Targeted Lymphodepletion Prior to Adoptive Cell TherapyActinium Pharmaceuticals Announces Phase 3 SIERRA Trial Dosimetry Results Support Low Dose Iomab-B for Targeted Lymphodepletion Prior to Adoptive Cell Therapy
finance.yahoo.com - December 9 at 9:29 AM
Actinium Pharmaceuticals Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH  2019 Annual MeetingActinium Pharmaceuticals Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting
finance.yahoo.com - December 9 at 9:29 AM
Actinium Pharmaceuticals to Present New Clinical Findings from SIERRA Trial Supporting the Iomab-ACT Program for Targeted Lymphodepletion for CAR-T and Adoptive Cell Therapies at ASH 2019Actinium Pharmaceuticals to Present New Clinical Findings from SIERRA Trial Supporting the Iomab-ACT Program for Targeted Lymphodepletion for CAR-T and Adoptive Cell Therapies at ASH 2019
finance.yahoo.com - November 6 at 9:19 AM
Actinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019Actinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019
finance.yahoo.com - November 6 at 9:19 AM
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient EnrollmentActinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
finance.yahoo.com - October 28 at 12:54 PM
Actinium Pharmaceuticals Inc.Actinium Pharmaceuticals Inc.
www.barrons.com - October 11 at 11:01 PM
Actinium Announces Participation at the 2019 Cell & Gene Meeting on the MesaActinium Announces Participation at the 2019 Cell & Gene Meeting on the Mesa
finance.yahoo.com - September 30 at 4:09 PM
Actinium Pharmaceuticals IncActinium Pharmaceuticals Inc
www.bloomberg.com - September 29 at 10:01 PM
Actinium Announces Iomab-B Poster Selected for Honorable Distinction Award at the 2019 Society of Hematologic Oncology Annual Meeting from Nearly Four Hundred AbstractsActinium Announces Iomab-B Poster Selected for Honorable Distinction Award at the 2019 Society of Hematologic Oncology Annual Meeting from Nearly Four Hundred Abstracts
finance.yahoo.com - September 23 at 2:01 PM
Actinium Pharmaceuticals to Present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & InvestmentActinium Pharmaceuticals to Present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment
finance.yahoo.com - September 17 at 5:15 AM
Sell-siders trim views on Inogen after Q2 miss and guidance cutSell-siders trim views on Inogen after Q2 miss and guidance cut
seekingalpha.com - August 8 at 12:29 PM
Actinium Achieves Fifty Percent Enrollment in the Pivotal Phase 3 SIERRA Trial for Iomab-BActinium Achieves Fifty Percent Enrollment in the Pivotal Phase 3 SIERRA Trial for Iomab-B
finance.yahoo.com - July 23 at 1:13 PM
This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.